Fenofibrate And Microvascular Events in Type 1 Diabetes (FAME 1) Trial

糖尿病是成年人失明的最常见原因之一。视力丧失是不可逆转的，是糖尿病最可怕的并发症。一种名为非诺贝特的降血脂药物，在澳大利亚上市，已被证明可将2型糖尿病患者的眼睛损伤减少35- 40%，并可预防1型糖尿病动物模型的眼睛损伤。这项研究将评估非诺贝特对450名患有早期糖尿病眼损伤的1型糖尿病成年人的潜在益处。

Diabetes is one of the commonest cause of blindness in adults. Vision loss, which is irreversible, is a most feared complication of diabetes. A blood fat lowering drug called fenofibrate, available in Australia, has been shown to reduce eye damage in people with Type 2 diabetes by 35-40%, and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate the potential benefits of fenofibrate in 450 adults with Type 1 diabetes who have early diabetic eye damage.